Summary This report describes the epidemiology, economic burden and treatment of osteoporosis in Switzerland.
Introduction
Osteoporosis is characterized by reduced bone mass and disruption of bone architecture, resulting in increased risks of fragility fractures which represent the main clinical consequence of the disease. Fragility fractures are associated with substantial pain and suffering, disability and even death for the affected patients and substantial costs to society. The aim of this report was to characterize the economic burden of osteoporosis in Switzerland in 2010 and beyond.
Methods
The literature on fracture incidence and costs of fractures in Switzerland was reviewed and incorporated into a model estimating the clinical and economic burden of osteoporotic fractures in 2010. Details of the methods used are found in Chapters 3 and 4 of the report "Osteoporosis in the European Union: Medical Management, Epidemiology and Economic Burden" [1] , published in 2013 in Archives of Osteoporosis.
Epidemiology of osteoporosis in Switzerland
For the purpose of this report, the population at risk of osteoporosis was considered to include men and women ≥50 years. The number of men and women ≥50 years of age amounted to 1,381,000 and 1,660,000, respectively, in Switzerland in 2010 (Table 1) .
In the population at risk, the number of individuals with osteoporosis-as defined by the WHO diagnostic criteria applied to the femoral neck-was estimated at 460,000 (Table 2 ). There were 20.8 DXA units/million inhabitants, and guidelines for the assessment and treatment of osteoporosis are available [2] . A country-specific FRAX model Table 1 Population at risk: men and women over the age of 50 years in Switzerland, 2010 [8] Age (years) Women Men All 50-59  556,000  545,000  1,101,000  60-69  477,000  435,000  912,000  70-79  351,000  275,000  626,000  80-89  238,000  116,000  354,000   80+  276,000  126,000  402,000  50+ 1,660,000 1,381,000 3,041,000 Table 2 Estimated number of women and men with osteoporosis (defined as a T-score≤ −2.5 SD) in Switzerland by age using female-derived reference ranges at the femoral neck, 2010 [9] Age group (years) Women Men 50-54  19,026  7,525  55-59  24,384  8,540  60-64  34,320  12,992  65-69  47,874  15,614  70-74  54,684  12,636  75-79  58,125  11,639  80+  130,272  20,916  50+ 368,685 89,862 Total  10,621  7,568  10,833  22,552 51,573  Men  50-74  1,233  2,306  1,588  8,205 13,333  75+  1,980  1,089  693  5,523  9,286  Total  3,213  3,395  2,282  13,729 22,619  Men and women  50-74  2,968  5,002  7,893  14,665 30,529  75+  10,866  5,960  5,221  21,615 43,663  Total  13,834 10,963  13,115  36,280 74,192 is also available for the assessment of fracture risk (http:// www.shef.ac.uk/FRAX/). Data on the incidence of hip, vertebral and forearm fractures are available for Switzerland [3] . The incidence for "other" fractures was derived as described in the EU27 report [1] (Table 3) .
The number of incident fractures in 2010 was estimated at 74,000 (Table 4) . Incident hip, clinical spine, forearm and other fractures were estimated at 14,000, 11,000, 13,000 and 36,000, respectively. Seventy percent of fractures occurred in women.
A prior fracture was defined as a fracture in an individual who was alive during the index year (i.e. 2010) and which had occurred after the age of 50 years and before 2010. In the population ≥50 years of age, the proportion of individuals who had suffered a fracture prior to 2010 was estimated at 2.0 % for hip and 2.7 % for clinical vertebral fractures. The estimated proportions of men and women with prior hip and vertebral fractures by age are presented in Table 5 . In the population over 50 years of age, the number of individuals with hip and vertebral fractures that occurred before 2010 was estimated at 62,000 and 81,000, respectively ( Table 6 ). Note that fractures sustained in 2010 were not included in the estimate.
The incidence of causally related deaths (per 100,000) in the first year after fracture by age is presented in Table 7 . The number of causally related deaths in 2010 was estimated at 756 (Table 8) . Hip, vertebral and other fractures accounted for 383, 208 and 165 deaths, respectively. Overall, approximately 61 % of deaths occurred in women.
Cost of osteoporosis in Switzerland including and excluding value of QALYs lost
For the purpose of this report, the cost of osteoporosis in 2010 (excluding value of QALYs lost) was considered to consist of three components: (i) cost of fractures that occurred in 2010 ("first year costs"), (ii) cost of fractures sustained prior to year 2010 but which still incurred costs in 2010 ("long-term disability cost") and (iii) cost of pharmacological fracture prevention including administration and monitoring costs ("pharmacological fracture prevention costs"). See Chapter 4 of the EU27 report [1] for further details.
In Switzerland, the costs of hip, vertebral and wrist fractures have been estimated to range from CHF 34,374 to 38,871, CHF 19,790 to 36,622 and CHF 7,000 to 25,454 depending on age, respectively [4] . One Swiss franc (CHF) corresponds to 0.82 euro. Costs for other fractures were estimated as described in Chapter 4 of the EU27 report [1] .
Long-term disability costs were estimated by multiplying the yearly cost of residing in a nursing home (CHF 74,294 [5] ) with the simulated number of individuals with prior fractures that had been transferred to a nursing home due to the fracture. Annual drug costs (CHF) for individual treatments are shown in Table 9 . In addition, it was assumed that patients on treatment made an annual physician visit costing CHF 91 [5] and a DXA scan costing CHF 75 [5] every second year to monitor treatment. The cost of osteoporosis in 2010 was estimated at CHF 2,050 million (Table 10 ). First year costs, subsequent year costs and pharmacological fracture prevention costs amounted to CHF 1,566 million, CHF 424 million and CHF 60 million, respectively. It is notable that pharmacological fracture prevention costs amounted to only 2.9 % of the total cost.
When stratifying costs of osteoporosis by fracture type, hip fractures were the most costly (CHF 900 million) followed by other fractures (CHF 700 million), spine fractures (CHF 246 million) and forearm fractures (CHF 144 million) (Table 11 and Fig. 1 ). Please note that costs for pharmacological fracture prevention were not included given that they could not be allocated to specific fracture sites.
The number of quality-adjusted life years (QALYs) lost due to osteoporosis in 2010 was estimated at 23,827 (Table 12). Prior fractures accounted for 54 % of the total loss and 69 % of the loss occurred in women. The monetary value of a QALY was varied between one and three times the gross domestic product (GDP) per capita set at CHF 68,040. Assuming a QALY is valued at two times the GDP/capita, the total cost of the QALYs lost was estimated at CHF 3.24 billion (Table 13) .
When the cost of osteoporosis was combined with the value of QALYs lost (valued at 2×GDP), the cost of osteoporosis amounted to CHF 5.3 billion in Switzerland in 2010. Incident fracture, prior fracture, pharmacological fracture prevention and value of QALYs lost accounted for 30, 8, 1 and 61 %, respectively.
Economic burden of osteoporosis up to 2025
The population above 50 years of age is expected to increase from 3.0 million in 2010 to 3.8 million in 2025, corresponding to an increase of 26 % (Table 14) . The total number of fractures was estimated to rise from 74,000 in 2010 to 99,000 in 2025 (Table 15) , corresponding to an increase of 33 %. Hip, clinical spine, forearm and other fractures increased by 4,900, 3,200, 3,500 and 13,010, respectively. The increase in the number of fractures ranged from 27 to 36 %, depending on the fracture site. The increase was estimated to be particularly marked in men (47 %) compared to women (27 %). It should be noted that the forecasts assume constant fracture incidence rates with time. However, small decreases in age-adjusted incidence for hip fracture incidence rates have been observed in recent years in Switzerland [6, 7] , potentially rendering the estimates biased upwards. The cost of osteoporosis (excluding value of QALYs lost) was estimated to rise from CHF 2.1 billion in 2010 to CHF 2.6 billion in 2025, corresponding to an increase of 29 % (Table 16). Costs incurred in women and men increased by 23 and 44 %, respectively.
The total number of QALYs lost due to fracture was estimated to rise from 24,000 in 2010 to 29,000 in 2025, corresponding to an increase of 24 % (Table 17) . The increase was estimated to be particularly marked in men (36 %) compared to women (18 %). Incident and prior fractures accounted for 64 and 36 % of the increase, respectively.
The cost of osteoporosis including value of QALYs lost was estimated to increase from approximately CHF 5.3 billion in 2010 to CHF 6.7 billion in 2025. The increase was estimated to be particularly marked in men (+39 %) compared to women (+20 %) (Table 18 ).
Treatment uptake
To estimate the uptake of individual osteoporosis treatments, sales data from IMS Health (2001-2011) were used to derive the number of defined daily doses (DDDs) sold per 100,000 persons aged 50 years or above (Fig. 2) .
Adjusting the sales data for compliance allowed for an estimation of the proportion of the population aged 50 years or above who received any osteoporosis treatment (see Chapter 5 of the report "Osteoporosis in the European Union: Medical Management, Epidemiology and Economic Burden" for further details [1] ). The proportion of persons over the age of 50 years who were treated increased from 1.7 % in 2001 to 4.9 % in 2011.
Treatment gap
In order to assess the potential treatment gap, the numbers of men and women eligible for treatment in Switzerland were defined as individuals with a 10-year fracture probability exceeding that of a woman with a prior fragility fracture derived from FRAX®, equivalent to a fracture threshold (see Chapter 5 of the main report for further details [1] ). Subsequently, these estimates were compared to the number of individuals who received osteoporosis treatment obtained from the analysis of IMS Health data. The treatment gaps in men and women were estimated at 36 and 58 %, respectively ( Table 19 ). Note that the estimate of the treatment gap is conservative given that it assumes that current use of osteoporosis treatments is only directed to men and women at high risk.
